The anti-angiogenic activity of NSITC, a specific cathepsin L inhibitor

Anticancer Research

Volumn 29, Issue 11, 2009, Pages 4473-4481

  Rebbaa, Abdelhadi ^a   Chu, Fei ^b   Sudha, Thangirala ^a   Gallati, Christine ^a   Dier, Usawadee ^a   Dyskin, Evgeny ^a   Yalcin, Murat ^a   Bianchini, Christine ^a   Shaker, Olfat ^c   Mousa, Shaker A ^a,d  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c CAIRO UNIVERSITY   (Egypt)

^d Vascular Vision Pharmaceuticals Co   (United States)

Author keywords

Angiogenesis; Cathepsin L; ECM; NSITC; Protease

Indexed keywords

ANGIOGENESIS INHIBITOR; CATHEPSIN L; FIBROBLAST GROWTH FACTOR; MATRIGEL; NSITC; UNCLASSIFIED DRUG; VASCULOTROPIN; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL ADHESION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL INTERACTION; CELL PROLIFERATION; CHORIOALLANTOIS; CONTROLLED STUDY; DRUG POTENCY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; CATHEPSIN L; CELL ADHESION; CELL MOVEMENT; CHICK EMBRYO; DIPEPTIDES; ENDOTHELIAL CELLS; HUMANS; MALE; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEASE INHIBITORS;

EID: 75149123481     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29: 15-18, 2002.
2. Folkman J: Angiogenesis inhibitors: a new class of drugs. Cancer Biology & Therapy 2: S127-133, 2003.
3. Verhoef C, de Wilt JH and Verheul HM: Angiogenesis inhibitors: perspectives for medical, surgical and radiation oncology. Current Pharmaceutical Design 12: 2623-2630, 2006.
4. Folkman J: Angiogenesis. Ann Rev Med 57: 1-18, 2006.
5. Pepper MS: Extracellular proteolysis and angiogenesis. Thrombosis and Haemostasis 86: 346-355, 2001.
6. Deryugina EI and Quigley JP: Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Reviews 25: 9-34, 2006.
7. Stetler-Stevenson WG: Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 103: 1237-1241, 1999.
8. Wagenaar-Miller RA, Gorden L and Matrisian LM: Matrix metalloproteinases in colorectal cancer: is it worth talking about? Cancer Metastasis Reviews 23: 119-135, 2004.
9. Heath EI, Burtness BA, Kleinberg L, Salem RR, Yang SC, Heitmiller RF, Canto MI, Knisely JP, Topazian M, Montgomery E, Tsottles N, Pithavala Y, Rohmiller B, Collier M and Forastiere AA: Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma. Investigational New Drugs 24: 135-140, 2006.
10. Fingleton B: MMPs as therapeutic targets - still a viable option? Seminars in Cell & Developmental Biology 19:61-8, 2008.
11. Duffy MJ: Proteases as prognostic markers in cancer. Clin Cancer Res 2: 613-618, 1996.
12. Lah TT and Kos J: Cysteine proteinases in cancer progression and their clinical relevance for prognosis Biol Chem 379: 125-130, 1998.
13. Joyce JA, Baruch A, Chehade K, Meyer-Morse N, Giraudo E, Tsai FY, Greenbaum DC, Hager JH, Bogyo M and Hanahan D: Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 5: 443-453, 2004.
14. Gocheva V and Joyce JA: Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 6: 60-64, 2007.
15. Hashmi S, Britton C, Liu J, Guiliano DB, Oksov Y and Lustigman S: Cathepsin L is essential for embryogenesis and development of Caenorhabditis elegans. J Biol Chem 277: 3477-3486, 2002.
16. Kane SE and Gottesman MM: The role of cathepsin L in malignant transformation. Semin Cancer Biol 1: 127-136, 1990.
17. Rousselet N, Mills L, Jean D, Tellez C, Bar-Eli M and Frade R: Inhibition of tumorigenicity and metastasis of human melanoma cells by anti-cathepsin L single chain variable fragment. Cancer Res 64: 146-151, 2004.
18. Gocheva V, Zeng W, Ke D, Klimstra D, Reinheckel T, Peters C, Hanahan D and Joyce JA: Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev 20: 543-556, 2006.
19. Zheng X, Chou PM, Mirkin BL and Rebbaa A: Senescence-initiated reversal of drug resistance: specific role of cathepsin L. Cancer Res 64: 1773-1780, 2004.
20. Zheng X, Chu F, Chou PM, Gallati C, Dier U, Mirkin BL, Mousa SA and Rebbaa A: Cathepsin L inhibition suppresses drug resistance in vitro and in vivo: a putative mechanism. Am J Physiol 296: C65-74, 2009.
21. Lombardi G, Burzyn D, Mundinano J, Berguer P, Bekinschtein P, Costa H, Castillo LF, Goldman A, Meiss R, Piazzon I and Nepomnaschy I: Cathepsin-L influences the expression of extracellular matrix in lymphoid organs and plays a role in the regulation of thymic output and of peripheral T-cell number. J Immunol 174: 7022-7032, 2005.
22. Yasuma T, Oi S, Choh N, Nomura T, Furuyama N, Nishimura A, Fujisawa Y and Sohda T: Synthesis of peptide aldehyde derivatives as selective inhibitors of human cathepsin L and their inhibitory effect on bone resorption. J Med Chem 41: 4301-4308, 1998.
23. Rebbaa A, Chou PM and Mirkin BL: Factors secreted by human neuroblastoma mediated doxorubicin resistance by activating STAT3 and inhibiting apoptosis. Mol Med 7: 393-400, 2001.
24. Chuan YC, Pang ST, Cedazo-Minguez A, Norstedt G, Pousette A and Flores-Morales A: Androgen induction of prostate cancer cell invasion is mediated by ezrin. J Biol Chem 287: 29938-29948, 2006.
25. Davis FB, Mousa SA, O'Connor L, Mohamed S, Lin HY, Cao HJ and Davis PJ: Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface. Circ Res 94: 1500-1506, 2004.
26. Davis FB, Tang HY, Shih A, Keating T, Lansing L, Hercbergs A, Fenstermaker RA, Mousa A, Mousa SA, Davis PJ and Lin HY: Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells. Cancer Res 66: 7270-7275, 2006.
27. Mousa SA, O'Connor LJ, Bergh JJ, Davis FB, Scanlan TS and Davis PJ: The proangiogenic action of thyroid hormone analogue GC-1 is initiated at an integrin. J Cardiovasc Pharmacol 46: 356-360, 2005.
28. Powell JA, Mohamed SN, Kerr JS, Mousa SA: Antiangiogenesis efficacy of nitric oxide donors. J Cell Biochem 80: 104-114, 2000.
29. Zheng X, Chu F, Mirkin BL, Sudha T, Mousa SA and Rebbaa A: Role of the proteolytic hierarchy between cathepsin L, cathepsin D and caspase-3 in regulation of cellular susceptibility to apoptosis and autophagy. Biochim Biophys Acta 1783: 2294-2300, 2008.
30. Stypmann J, Glaser K, Roth W, Tobin DJ, Petermann I, Matthias R, Mönnig G, Haverkamp W, Breithardt G, Schmahl W, Peters C and Reinheckel T: Dilated cardiomyopathy in mice deficient for the lysosomal cysteine peptidase cathepsin L. Proc Natl Acad Sci USA 99: 6234-6239, 2002.
31. Felbor U, Kessler B, Mothes W, Goebel HH, Ploegh HL, Bronson RT and Olsen BR: Neuronal loss and brain atrophy in mice lacking cathepsins B and L. Proc Natl Acad Sci USA 99: 7883-7888, 2002.
32. Benavides F, Starost MF, Flores M, Gimenez-Conti IB, Guenet JL and Conti CJ: Impaired hair follicle morphogenesis and cycling with abnormal epidermal differentiation in nackt mice, a cathepsin L-deficient mutation. Am J Pathol 161: 693-703, 2002.